title: Current management and future perspectives of overactive bladder (OAB) pharmacotherapy.
abstract: Overactive bladder (OAB) is a condition characterized by urgency with or without urgency incontinence (UI), usually with increased daytime frequency and nocturia, which affects even 8-14% of adult population. The gold standards of OAB treatment are antimuscarinics, although this clinical entity is often poorly controlled with these agents. Thus, a progress in OAB pharmacotherapy is expected and takes place. The purpose of this article is to short review the present management of the overactive bladder with paying special attention on development of new drugs indicated for OAB treatment.
authors: Department of Pathophysiology, Jagiellonian University, Medical College Czysta 18, 31-121 Kraków, Poland. lukaszd@mp.pl
authors: Łukasz
authors: Ł
authors: Dobrek
authors: Kajetan
authors: K
authors: Juszczak
authors: Marek
authors: M
authors: Wyczółkowski
authors: Piotr Jan
authors: PJ
authors: Thor
mesh_terms: D000818:Animals; D015195:Drug Design; D015507:Drugs, Investigational / Q000737:chemistry / Q000627:therapeutic use*; D006801:Humans; D018727:Muscarinic Antagonists / Q000627:therapeutic use; D018377:Neurotransmitter Agents / Q000737:chemistry / Q000627:therapeutic use*; D016896:Treatment Outcome; D001743:Urinary Bladder / Q000187:drug effects* / Q000503:physiopathology; D053201:Urinary Bladder, Overactive / Q000188:drug therapy* / Q000503:physiopathology
chemical_list: D015507:Drugs, Investigational; D018727:Muscarinic Antagonists; D018377:Neurotransmitter Agents